Floatz logo

MANNITOL

Nonsmall Cell Lung Cancer

Wake Forest University Health SciencesSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Nonsmall Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
hs-10365
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 2CCC
Gefetinib
Samsung Medical Center
Phase 2CCC
1.0% ip-001 for
Immunophotonics, Inc.
Phase 1/2CC
Vmd-102
VM Discovery, Inc.
Phase 1/2CC
XP-102
Xynomic Pharmaceuticals, Inc.
Phase 1/2CC

View all 14 →

Same molecule, other indications

MANNITOL is also rated in:

cystic fibrosisDormant
BB
Indicative ·
69 / 100
View asset →
Intracranial HypertensionDormant
BB
Indicative ·
67 / 100
View asset →
traumatic brain injuryDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →